5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma

doi:10.4251/wjgo.v17.i11.111142

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (753)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

HTML

221

Figures (1-7)

Tables (1-1)

Sum=373

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

289

Sum=337

Nov 15, 2025 (publication date) through May 2, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Nov 15, 2025; 17(11): 111142
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111142

Table 1 clinicopathologic parameters of 110 hepatocellular carcinoma patients, n (%)

Characteristics	Patients	5’-tiRNA-Lys-CTT		P value
Characteristics	Patients	High	Low	P value
Number	110	55 (50)	55 (50)
Gender				0.2343
Male	70 (63.6)	38 (34.5)	32 (29.1)
Female	40 (36.4)	17 (15.5)	23 (20.9)
Age (years)				0.6884
< 60	38 (34.5)	18 (16.4)	20 (18.2)
≥ 60	72 (65.5)	37 (33.6)	35 (31.8)
Tumor size (cm)				0.0174^a
< 5	40 (36.4)	26 (23.6)	14 (12.7)
≥ 5	70 (63.6)	29 (26.4)	41 (37.3)
BCLC stage				0.0064^b
0/A	44 (40.0)	29 (26.4)	15 (13.6)
B/C/D	66 (60.0)	26 (23.6)	40 (36.4)
Tumor differentiation				0.2290
Well/moderate	72 (65.5)	39 (35.5)	33 (30.0)
Poor	38 (34.5)	16 (14.5)	22 (20.0)
Metastasis				0.0348
Negative	49 (44.5)	30 (27.3)	19 (17.3)
Positive	61 (55.5)	25 (22.7)	36 (32.7)
Cirrhosis of the liver				0.0161^a
Absence	38 (34.5)	13 (11.8)	25 (22.7)
Presence	72 (65.5)	42 (38.2)	30 (27.3)

^aP < 0.05.

^bP < 0.01.

BCLC: Barcelona Clinic Liver Cancer.

Full Size Table

Citation: Yuan J, Gu WC, Xu TX, Shen XJ, Li X, Shen L, Zhang Y, Ju SQ. 5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(11): 111142
URL: https://www.wjgnet.com/1948-5204/full/v17/i11/111142.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.111142

Yuan J, Gu WC, Xu TX, Shen XJ, Li X, Shen L, Zhang Y, Ju SQ. 5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(11): 111142 [PMID: 41281472 DOI: 10.4251/wjgo.v17.i11.111142]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.